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E2F1 drives chemotherapeutic drug resistance via ABCG2
MT Rosenfeldt1, LA Bell1, JS Long1, J O’Prey1, C Nixon1, F Roberts2, C Dufe`s3 and KM Ryan1
Multidrug resistance is a major barrier against successful chemotherapy, and this has been shown in vitro to be often caused by
ATP-binding cassette (ABC) transporters. These transporters are frequently overexpressed in human cancers and confer an adverse
prognosis in many common malignancies. The genetic factors, however, that initiate their expression in cancer are largely
unknown. Here we report that the major multidrug transporter ABCG2 (BCRP/MXR) is directly and speciﬁcally activated by the
transcription factor E2F1—a factor perturbed in the majority of human cancers. E2F1 regulates ABCG2 expression in multiple cell
systems, and, importantly, we have identiﬁed a signiﬁcant correlation between elevated E2F1 and ABCG2 expression in human lung
cancers. We show that E2F1 causes chemotherapeutic drug efﬂux both in vitro and in vivo via ABCG2. Furthermore, the E2F1–ABCG2
axis suppresses chemotherapy-induced cell death that can be restored by the inhibition of ABCG2. These ﬁndings therefore identify
a new axis in multidrug resistance and highlight a radical new function of E2F1 that is relevant to tumor therapy.
Oncogene (2014) 33, 4164–4172; doi:10.1038/onc.2013.470; published online 25 November 2013
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INTRODUCTION
During tumor development, a multitude of events occur, which
inﬂuence disease progression and affect the efﬁcacy of tumor
therapy. An event that is considered extremely common in many
cancers is perturbation of the transcription factor E2F1.1,2 In
normal cells, E2F1 is a major determinant of the commitment to
cell cycle progression, and E2F1’s activity is kept in check by the
retinoblastoma protein, pRB.3 In addition to its effects on cell cycle
progression, E2F1 is best characterized for its role in apoptosis
induction and has also been shown to regulate diverse processes
such as differentiation and autophagy.4,5 E2F1 mediates cell death
largely by transcriptional activation of pro-apoptotic target genes
or repression of anti-apoptotic genes and has been demonstrated
to render cancer cells more susceptible to certain chemo-
therapeutic drugs.6 It is currently not clear, however, as to what
extent these and also as-yet unidentiﬁed activities of E2F1 may be
relevant to E2F1’s role in the pathogenesis and treatment of
cancer.7
Multidrug resistance occurs in nearly all cancers and is a serious
impediment to successful chemotherapy.8 Major effectors of drug
resistance are multidrug transporters that can be elevated and/or
hyperactivated during the genesis of cancer. The ATP-binding
cassette (ABC) multidrug transporters such as P-glycoprotein
(MDR1/ABCB1), MRP1 (ABCC1) and ABCG2 (BCRP/MXR) are
considered responsible for the majority of drug efﬂux in human
cancer in vitro.8,9 A high expression of ABC transporters has been
repeatedly linked to an adverse prognosis in common forms of
cancer.10
In order to understand drug resistance mediated by multidrug
transporters, it is critical to know the factors that control their
expression so that we can predict when the activity of any given
transporter may be relevant. We report here the remarkable
discovery that ABCG2 is under the control of E2F1 in multiple cell
systems, and we show that the E2F1–ABCG2 axis regulates
chemotherapeutic drug efﬂux and drug resistance. When coupled
with the fact that E2F1 is frequently perturbed in human cancer,
these ﬁndings represent a distinct new function for E2F1 that may
be relevant for the development and treatment of human cancer.
RESULTS
To gain insights into the E2F1 function, we performed microarrays
using tetracycline-inducible cells expressing either wild-type E2F1
or the DNA-binding defective mutant E2F1-E132 to identify genes
induced by E2F1.11 This intriguingly revealed that the highest
E2F1-induced messenger RNA (mRNA) encodes the multidrug
transporter ABCG2 (see Supplementary Information for microarray
dataset). Direct mRNA and protein analyses in these cells showed
that ABCG2 was strongly induced by wild-type E2F1 but not
the mutant E2F1-E132 (Figures 1a and b and Supplementary
Figures S1a and S1b). To test whether the induction of ABCG2 is a
cell line-speciﬁc phenomenon, a panel of cell lines from different
tissues were engineered to express E2F1 fused to the hormone-
binding domain of the estrogen receptor. Tamoxifen-induced
activation of E2F1-ER in these cells resulted in increased levels of
ABCG2 mRNA and protein in all cases (Figures 1c and d). In contrast,
no elevation of the other major ABC transporters was observed
following the activation of E2F1 (Supplementary Figure S2).
To test whether ABCG2 is a direct target of E2F1, we used the
E2F1-ER system. This revealed that E2F1 can induce ABCG2 mRNA
levels in both the absence and presence of the protein synthesis
inhibitor cycloheximide, indicating a direct relationship between
E2F1 and ABCG2 (Supplementary Figure S3). In this regard, by
infecting primary Tig3 lung ﬁbroblasts with E1a, we also
determined whether pRb function was modulating ABCG2
expression at different phases of the cell cycle, but this appeared
not to be the case (Supplementary Figure S4). As a result, this
caused us to consider whether ABCG2 is a direct transcriptional
target of E2F1. Analysis of the ABCG2 promoter revealed a
potential E2F1 binding site upstream of the transcription start site
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(Figure 2a). To test whether this site was responsive to E2F1, cells
were transfected with an expression vector for either wild-type
E2F1 or E2F1-E132, together with luciferase reporter constructs
containing increasing lengths from the ABCG2 promoter.12 This
revealed that the ﬁrst 243 nucleotides upstream of the ABCG2
transcription start site are markedly responsive to E2F1 (Figure 2b).
No activation was seen with the DNA-binding defective mutant
E2F1-132E (Figure 2b). Moreover, deletion of the putative E2F1
binding site in the  243 construct rendered this construct
unresponsive to E2F1 (Figure 2c). Finally, we performed chromatin
immunoprecipitations (ChIPs) with E2F1, which conﬁrmed that
E2F1 indeed binds this region of the ABCG2 promoter (Figure 2d).
The regulation of ABCG2 is a complex process, for example,
alternative promotors and micro RNAs impact on ABCG2
expression in different cell types, and it cannot be ruled out that
E2F1 also interacts with these regulators.10 However, our collective
data show that ABCG2 is a direct target gene of E2F1.
The fact that E2F1 activates a multidrug transporter naturally
caused us to consider whether E2F1 can cause efﬂux of
chemotherapeutic drugs from cells via ABCG2. In this regard, we
observed that ABCG2 accumulates at the cell membrane,
following the activation of E2F1, making drug efﬂux highly likely
(Supplementary Figure S5). Saos-2 TetOn E2F1 cells as well as
MDA-MB-231 and BJ lung ﬁbroblasts containing E2F1-ER were
therefore tested for their ability to efﬂux the ﬂuorescent
chemotherapeutic mitoxantrone—a well characterized substrate
of ABCG2.9 In each case, activation of E2F1 with doxycycline (DOX)
(TetOn E2F1) or 4-hydroxytamoxifen (TAM) (E2F1-ER) caused
marked mitoxantrone efﬂux with a particularly marked effect
being observed in BJ and MDA-MB-231 cells (compare blue line/
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Figure 1. E2F1 regulates ABCG2 expression. (a, b) Saos-2 TetOn E2F1 cells were induced with 1mM doxycycline (DOX) for the indicated times.
Levels of E2F1 and ABCG2 mRNA (a) and protein (b) were measured by western blotting. (c, d) A panel of human cell lines was infected with a
retrovirus expressing E2F1-ER and were treated with 500 nM 4-hydroxytamoxifen (TAM) for 24 h to activate E2F1 or with EtOH as control.
The effect on ABCG2 mRNA and protein levels was assessed by quantitative PCR (c) and western blotting (d).
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bar ‘E2F1 ON’ with green line/bar ‘E2F1 OFF’, Po0.01) (Figure 3a).
To investigate this effect further, efﬂux in MDA-MB-231 cells was
compared with that in cells expressing E2F1-ER, E2F1-132E-ER,
ABCG2 or an empty viral vector as control. As would be expected,
maximal efﬂux was observed in cells expressing exogenous
ABCG2, whereas no ABCG2 induction or efﬂux was observed in
empty vector (pBabe) cells or cells expressing E2F1-132E-ER. This
indicates that the E2F1-mediated induction of endogenous ABCG2
and drug efﬂux was speciﬁc for wild-type E2F1 (Figure 3b). Similar
results were also obtained in BJ cells (Supplementary Figure 6).
To examine whether E2F1 can cause drug efﬂux in vivo, we took
advantage of the fact that D-luciferin (the substrate for ﬁreﬂy
luciferase) is a speciﬁc target of ABCG2, but not other drug
transporters.13 MDA-MB-231 cells were therefore engineered to
express E2F1-ER and also the gene for luciferase. Cells were then
injected into mice to form a xenograft. Groups of mice (n¼ 5 per
group) were subsequently treated either with tamoxifen or ethanol
as control. D-luciferin was then administered systemically to each
group of mice, and luciferase activity was measured over time
in vivo as a readout of the efﬂux activity. Although the luciferase
signal increased over time and plateaued after 40min in control
mice treated with ethanol, luciferase activity did not increase in
mice that had been pre-treated with TAM to activate E2F1 (and
therefore ABCG2) (Figure 3c). This indicates that the frequent
elevation of E2F1 in tumors may well affect the availability, and
therefore the efﬁcacy, of a systemically administered drug.
To test whether E2F1-induced drug efﬂux was speciﬁcally
mediated by ABCG2, we infected E2F1-ER cell lines with short
hairpin RNAs (shRNAs) targeting ABCG2 or a scrambled hairpin
(NTC) as control (Figure 4a).14 shRNAs against ABCG2 effectively
abolished ABCG2 induction, following the activation of E2F1 with
TAM (Figure 4a). Strong efﬂux of mitoxantrone was observed
following E2F1 activation in the cells containing the scrambled
shRNA or the empty lentiviral vector (pLKO) (Figure 4b). In
contrast, each of the lines containing a hairpin to knockdown
ABCG2 underwent very little, if any, efﬂux following the activation
of E2F1, conﬁrming that efﬂux induced by E2F1 is mediated via
ABCG2 (Figure 4b).
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Figure 2. E2F1 regulates ABCG2 transcription via an element in the ABCG2 promoter. (a) Schematic of the ABCG2 promoter region. Reporter
construct lengths are indicated. Sequence analysis also revealed a putative E2F1 binding site between  36 and  47 nucleotides upstream of
the transcription start site. (b) Luciferase reporter constructs containing elements from the ABCG2 promoter as depicted in (a) were
transfected into Saos-2 cells together with either wild-type E2F1 (wt), mutant E2F1 (E132) or CMV empty vector as control. Fold activation of
each reporter is shown relative to CMV empty vector control. (c)  243-Luc and a mutant of this construct with the putative E2F1 binding site
deleted (del E2F1) were transfected into Saos-2 cells with either wild-type E2F1 or empty CMV vector as control. Fold activation of each
reporter is shown relative to CMV-empty vector control. (d) ChIP assays were performed using the indicated antibodies (abs) on Saos-2 TetOn-
E2F1 cells either in the absence or in the presence of 1mM doxycycline (DOX) for 24 h. Promoter binding is shown relative to non-induced
(DOX) controls.
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A number of pharmacological inhibitors of multidrug resistance
pumps have been described.9 We decided to test, therefore,
whether the ABCG2-speciﬁc efﬂux inhibitor Ko14315 could revert
efﬂux induced by E2F1. MDA-MB-231 E2F1-ER and BJ E2F1-ER cells
were treated with Ko143 and efﬂux of mitoxantrone measured as
before. In both cell lines, the extensive efﬂux caused by E2F1 could
be practically entirely reverted by treatment with Ko143, not only
indicating that this effect of E2F1 can be successfully modulated
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Figure 3. E2F1 causes drug efflux in vitro and in vivo. (a, b) Saos-2 TetOn-E2F1 cells as well as MDA-MB-231 and BJ cells that had been infected
as indicated with retroviruses expressing E2F1, mutant E2F1 (132E), ABCG2 or pBabe as control were incubated with either doxycycline or
4-hydroxytamoxifen (TAM) as shown for 24 h. Cells were then incubated where indicated with 20 mM mitoxantrone for 1 h. Mitoxantrone was
then removed and the extent of drug efflux (as determined by a decrease in fluorescence) was measured 3 h later by flow cytometry. Bar
graphs (right of the corresponding histogram in (a) and below the corresponding histogram in (b)) represent the median fluorescence
intensity of corresponding FACS profiles as a surrogate quantification of drug efflux. (c) Athymic mice (n¼ 5 in each group) were
subcutaneously injected with luciferase- and E2F1-ER-expressing MDA-MB-231 cells to form xenografts. E2F1 was induced where indicated by
intraperitoneal injection of TAM. Twenty-four hours later, mice were given an intraperitoneal injection of D-luciferin. After 10min, mice were
imaged every 10min for 1 h and luminescence was recorded. Error bars indicate s.d. Representative images are of mice injected with either
ethanol or TAM. The images are taken 1 h after injection of D-luciferin (c, right side).
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pharmacologically but also once again showing that E2F1-induced
drug efﬂux is mediated signiﬁcantly and primarily by ABCG2
(Figure 4c).
Our results implied that E2F1-induced drug efﬂux could actually
reduce cell death caused by the administration of chemother-
apeutic drugs. If so, the expression of E2F1 should cause resistance
to a drug that is a known substrate of ABCG2, and this resistance
should be reversed by inhibition of ABCG2. To test this BJ and
MDA-MB-231 E2F1-ER cells were incubated with mitoxantrone
either in the absence or presence of TAM, and cell death was
determined by assessment of cell membrane permeability
(Figures 5a and b). In both cases, activation of E2F1 could
markedly reduce cell death from mitoxantrone (Po0.01) and this
cell death resistance could be reverted by the treatment with
Ko143 (Po0.01) (Figures 5a and b). Ko143 did not enhance cell
death in the absence of mitoxantrone with or without the
activation of E2F1. These data therefore show that the effective-
ness of treating tumor cells with chemotherapeutic drugs can be
markedly dampened due to the activation of ABCG2 by E2F1.
In light of our data showing that ABCG2 is regulated by E2F1 in
many different cell types, we asked whether these observations
were linked in human cancer. Lung cancer is the most common
cancer worldwide, and lung tumors have been reported in
separate studies to contain either high levels of E2F1 or ABCG2
with both markers individually indicating poor prognosis.16,17 We
therefore stained tissue microarrays containing non-small cell lung
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Figure 5. Activation of E2F1 impedes chemotherapy-induced death
via ABCG2. (a, b) MDA-MB-231 E2F1-ER cells (a) and BJ E2F1-ER cells
(b) were incubated with TAM or EtOH as indicated for 24 h.
Mitoxantrone and Ko143 (or DMSO as control) were then added
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cancer samples as well as normal lung for E2F1 and ABCG2. There
was no signiﬁcant staining for E2F1 and ABCG2 in normal lung
tissue (Figure 6a). Similarly, tumor samples with normal levels of
E2F1 rarely exhibited elevated staining for ABCG2 (Figure 6a). In
contrast, tumors with areas of higher staining for E2F1 were
frequently associated with high levels of ABCG2 in the same
regions on sequential sections (Figure 6a). Across the entire tissue
microarrays containing 54 tumors in total, 26 tumors had regions
positive for high levels of E2F1 and 21 of these showed coincident
elevated staining for ABCG2. Reciprocally, of 29 tumors with
ABCG2 levels similar to normal lung, only 5 had regions with
elevated levels of E2F1 (Supplementary Tables S1 and S2). This
E2F1 and ABCG2 association was found to be highly signiﬁcant by
Fisher’s exact test (Po0.01).
To test whether the correlation between E2F1 and ABCG2 levels
in human lung cancer was causally related, we analyzed E2F1 and
ABCG2 protein levels in a set of non-small cell lung cancer cell
lines (Figure 6b). Knockdown of E2F1 by RNA interference in lines
that express high levels of both E2F1 and ABCG2 caused a marked
decrease of ABCG2, indicating that E2F1 was at least in part
responsible for the elevated levels of ABCG2 in these cells
(Figure 6c).
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Finally, we tested whether E2F1 was involved in drug efﬂux in
lung cancer cells. First, we infected H1299 non-small cell lung
cancer cells with E2F1-ER, which revealed that the activation of
E2F1 in these cells caused efﬂux of mitoxantrone and that this
efﬂux could be completely reversed by the treatment with the
ABCG2 inhibitor, Ko143 (Figure 6d). Similar results were also
observed for the chemotherapeutic photosensitizer pheophorbide
A (Supplementary Figure 7), which is a known ABCG2 substrate
that has been shown to sensitize cells to apoptosis.18,19 Second,
we measured efﬂux in LDAN and A549 cells, as we had found that
ABCG2 expression was at least partly dependent on E2F1 in these
lines (Figure 6c). This showed that efﬂux was diminished as a result
of E2F1 knockdown in both cell lines with E2F1 knockdown having
an intermediate effect when compared with the treatment with
Ko143, which causes maximal inhibition of ABCG2 (Figure 6e).
When taken together and in line with the association between
E2F1 and ABCG2 in human lung cancer, these data conﬁrm that
the E2F1/ABCG2 axis is active in human lung cancer cells.
DISCUSSION
In this study, we show that activation of ABCG2 by E2F1 causes
drug efﬂux in multiple cell lines and in a xenograft model, and that
this can lead to impedance of chemotherapy-induced cell death.
Importantly, we also identify that E2F1 and ABCG2 protein levels
are signiﬁcantly colocalized in the most common form of lung
cancer, and that endogenous ABCG2 levels are regulated by E2F1
expression in human lung cancer cell lines. Although both E2F1 and
ABCG2 have previously been independently described to be poor
prognostic indicators for lung cancer,16,17,20 this is the ﬁrst study to
report that these two events are linked. Several other transcription
factors have also been shown to regulate ABCG2,10 but the fact that
E2F1 is frequently elevated in human cancer means our ﬁndings
add signiﬁcantly to our understanding of how this multidrug
transporter can be upregulated during tumor development. We
therefore consider that the drug efﬂux via ABCG2 is a novel and
may be a common phenotypic effect of activating E2F1.
A large number of reports have shown that E2F1 is a pro-death
effector,2 but more recently pro-survival roles for E2F1 have also
been reported.21 In particular, one report has shown that E2F1 can
cause drug resistance via the activation of DN-p73, which leads to
the repression of the microRNA, miR-205.22 This microRNA controls
the expression of Bcl-2 and the ABC transporters ABCA2 and
ABCA5, such that when miR-205 expression is repressed, these
factors are elevated and promote cell survival.22 To the best of our
knowledge, however, the study we present here is the ﬁrst report
to show that E2F1 directly activates one of the three major
multidrug transporters implicated in cancer—ABCG2. As such, this
study not only advances what we know about the regulation of
ABCG2 but also highlights an extraordinary new function for E2F1
that may be relevant to both tumor development and cancer
therapy. In this regard, this study may therefore help in the design
of more targeted clinical trials that will ascertain the importance of
the E2F1/ABCG2 axis in mediating impaired therapeutic responses
and patient outcome following chemotherapy. In this regard,
future studies should focus on ascertaining whether this efﬂux axis
is active in a variety of tumor types and whether this affects the
clinically relevant drugs for each disease.
MATERIALS AND METHODS
Chemicals and reagents
All chemicals and reagents were purchased from Sigma Aldrich
(Gillingham, UK) unless otherwise indicated. Ko143 was from Tocris
Bioscience (R&D Systems Europe, Abingdon, UK) and D-Luciferin from Gold
Biotechnology (St Louis, MO, USA). The ChIP Assay Kit was from Millipore
(Watford, UK) and the human lung cancer tissue microarray was from Folio
Biosciences (Columbus, OH, USA).
Plasmids
pTRE-E2F1 constructs were generated by cloning either wild-type E2F1 (pTRE-
E2F1) or the DNA-binding defective E2F1 mutant 132E (TetOn-E2F1-132E) into
the tetracycline-responsive plasmid pTRE (Clontech, Mountain View, CA, USA).
pBabe vectors (expressing E1a, wild-type E2F1 or E2F1-132E) fused
to a tamoxifen-responsive element of the estrogen receptor (pBabe E1a-
ER, pBabe E2F1-ER or pBabe E2F1-132E-ER) have been described
previously.23
Luciferase reporter constructs were in pGL3 (pGL3 ABCG2 243,  312,
 628 and  1285) and have been described previously.12 In order to
generate a reporter construct lacking a potential E2F1 binding site,  243-Luc
was ampliﬁed with the following primers: E2F1 BS1 ( 36 to  47) deletion
primers: F, GTC GGG GCC ACG CCT CAC CCC CCG ACC TGG GGA AAC CCG G;
R, CCG GGT TTC CCC AGG TCG GGG GGT GAG GCG TGG CCC CGA C
Antibodies
The following antibodies were used for western blotting (WB), immuno-
precipitation in ChIP assays (IP), immunoﬂuorescence (IF) and immunohis-
tochemistry (IHC).
Target Clone/cat no. Manufacturer Application
ABCG2 BXP-21 Millipore WB, IF, IHC
ABCG2 5D3 Pharmingen (BD
Biosciences,
Oxford, UK)
IF
E1a M58 Pharmingen IP
E2F1 KH95 and KH20 Millipore WB, IP, IHC
Estrogen receptor
alpha (ER-a)
HC-20 Santa Cruz
(Dallas, TX, USA)
IF
Actin 9212 Cell Signaling
(Danvers, MA, USA)
WB
Cell culture and infections
Cells were grown in DMEM supplemented with 10% FBS and penicillin/
streptomycin. Retroviral and lentiviral infections were performed as
described.23,24
Cell line generation
Cell lines stably expressing inducible E2F1-ER or E2F1-132E-ER were
produced by retroviral infection and antibiotic selection. Knockdown of
ABCG2 or E2F1 was achieved by means of the lentiviral pLKO.1-system.
TetOn E2F1-inducible cell lines were all generated in Saos-2 cells. Cells were
ﬁrst transfected with the TetOn regulator plasmid and cloned and tested for
good inducibility of a Tet-responsive luciferase plasmid, Tet-Luc. A cell clone
that showed good induction was subsequently transfected with either pTRE-
E2F1 or pTRE-E2F1-132E together with pIRES-Hyg as a selectable marker.
Clones were then again selected for good inducibility of E2F1 trans-genes.
Cell line authentication
All cell lines were authenticated using the Applied Biosystems AmpF/STR
Identiﬁler Kit. Data were analyzed using Applied Biosystems Genemapper
software and comparing the data with ATCC (LGC standards) and DSMZ
databases.
Immunoblotting
Western analysis was done as previously described25 using antibodies
against: ABCG2 (Millipore, Watford, UK), E2F1 (Millipore) and actin (Cell
Signaling) as outlined above.
Immunoﬂuorescence
Cells grown on coverslips were ﬁxed in 4% paraformaldehyde, permea-
bilized with PBS (1% BSA, 0.2% TritonX) and stained for ABCG2 (Chemicon)
and estrogen receptor-a (Santa Cruz). Confocal microscopy was used to
visualize ABCG2 expression and E2F1 cytoplasmic–nuclear translocation.
Quantitative real-time PCR
RNA isolation, complimentary DNA synthesis and quantitative real-time
PCR were performed using the DynamoSYBRGreen 2-step quantitative
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real-time PCR kit from Finnzymes (Thermo Fisher, Loughborough, UK)
following manufacturer’s instructions.
The following primers were used for quantitative real-time PCR of ABC-
transporter transcripts and E2F1 mRNA, or for the ampliﬁcation of genomic
DNA from ChIP assays.
Target Sequence 50 to 30 (forward, reverse) Application
Human ABCG2 Qiagen, QuantiTect Primer Assay,
Hs_ABCG2_1_SG*
qPCR of mRNA
transcripts
Human E2F1 Qiagen, QuantiTect Primer Assay,
Hs_E2F1_1_SG*
qPCR of mRNA
transcripts
Human ABCB1/
MDR1/PgP
Qiagen, QuantiTect Primer Assay,
Hs_ABCB1_1_SG*
qPCR of mRNA
transcripts
Human ABCC1/
MRP1
QSiagen, QuantiTect Primer Assay,
Hs_ABCC1_1_SG*
qPCR of mRNA
transcripts
Human 18s GTAACCCGTTGAACCCCATT,
CCATCCAATCGGTAGTAGCG
qPCR of mRNA
transcripts
Promoter region
of human ABCG2
TCACCAGAAACCACCCATTT,
TGGGCTGATCAGTACCTCGT
ChIP
Promoter region
of human actin B
GGTGAACCCAGAAAAACTGG,
GTGTGTGGAGATCCCTCCTG
ChIP
Promoter region of
human CDC6
AAAGGCTCTGTGACTACAGCCA,
GATCCTTCTCACGTCTCTCACA
ChIP
* Sequence not disclosed by the manufacturer.
Chromatin immunoprecipitation
Chromatin was isolated from Saos-2 TetOn-E2F1 cells treated with or without
DOX for 24h using the ChIP Assay Kit from Millipore following manufacturer’s
instructions. qPCR was used to detect ABCG2 promoter enrichment.
Drug efﬂux
Efﬂux assays were performed as described.26 In brief, in vitro efﬂux was
measured after incubation for 1 h (30min for pheophorbide A) with
ﬂuorescent substrate mitoxantrone (pheophorbide A, 1mM) followed by 3 h
(1 h for pheophorbide A) efﬂux. In vivo efﬂux was quantiﬁed relative to the
chemiluminescence 10min after the injection of luciferin.13 Statistical
analyses were undertaken via a Student’s t-test.
Cell death assay
After treatment for the indicated times, unﬁxed cells were analyzed by ﬂow
cytometry for propidium iodide permeability as an assessment of
membrane integrity and cell viability. Statistical analyses were undertaken
via a Student’s t-test.
Cell cycle and ABCG2 expression analysis by ﬂow cytometry
Following the designated treatments, cells were detached with PBS-EDTA
and were stained with anti-ABCG2 antibody and subsequently with a FITC-
conjugated secondary antibody before ﬁxation in methanol. After a
minimum of 2 h ﬁxation at 4 1C, cells were re-suspended in PBS containing
propidium iodide. Cells were then analyzed by ﬂow cytomtery for ABCG2
levels and DNA content. ABCG2 expression for each phase of the cell cycle
(identiﬁed by appropriate gating) was expressed relative to total ABCG2
expression after induction with tamoxifen.
Luciferase assay
Luciferase assays were performed using a panel of ABCG2 reporter
constructs kindly provided by Doug Ross and were used as described.12
SAOS-2 cells were transfected with 5mg of ABCG2 Luciferase constructs and
0.1mg of pcDNA3-E2F1 or empty vector. Twenty-four hours later, cells were
lysed in luciferase lysis buffer according to manufacturer’s instructions and
analyzed for luciferase activity (Promega, Madison, WI, USA).
Immunohistochemistry
IHC was performed on formalin-ﬁxed tissue microarrays using pH 6 heat-
induced epitope retrieval. The DAKO Envision Kit was used to amplify and
visualize antibody staining. Staining for ABCG2 was as described previously.27
RNA interference
The pLKO.1 lentiviral vector (expressing a blasticidine resistance) contain-
ing the following shRNA sequences was used to bring about knockdown of
speciﬁc target genes.
shRNA (human) Sequence (50 to 30)
shNTC (non-targeting control) TAAGGCTATGAAGAGATAC
shABCG2-1 CCTTCTTCGTTATGATGTTTA
shABCG2-2 GCTGTGGCATTAAACAGAGAA
shABCG2-3 CCTGCCAATTTCAAATGTAAT
shE2F1 CATCCAGCTCATTGCCAAGAA
In vivo-efﬂux studies/xenograft experiments
Ethical approval to perform animal experiment was granted from the
relevant institutions. Experiments were conducted on the basis of
previously published data.13 A number of 5 106 MDA-MB-231 E2F1-ER
cells were injected into both ﬂanks of 6- to 8-week-old athymic, nude mice.
E2F1 was induced 24 h later by intraperitoneal injection of TAM (0.1mg) or
an equal volume of ETOH/sunﬂower oil solvent in control mice (n¼ 5 in
each group). On the following day, D-luciferin (150mgkg 1) was injected
intraperitoneally to anesthesized (2.5% isoﬂuorane) mice and signal
acquisition started immediately thereafter with readings every 10min for
80min. The relative increase in luminescence to the 10min reading of each
mouse was calculated and blotted against time as a readout of ABCG2—
efﬂux function.
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